Addex Therapeutics Ltd
SIX:ADXN
Addex Therapeutics Ltd
SIX:ADXN
Price:
0.071 CHF
-3.79%
Updated:
May 15, 2024
Addex Therapeutics Ltd
Income from Continuing Operations
|
Addex Therapeutics Ltd
Income from Continuing Operations Peer Comparison
Comparables:
ADCT
ACIU
CRSP
BSLN
IDIA
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Addex Therapeutics Ltd
SIX:ADXN
|
Income from Continuing Operations
-CHf10.6m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Income from Continuing Operations
-$234.5m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Income from Continuing Operations
-CHf54.2m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Income from Continuing Operations
-$217.1m
|
CAGR 3-Years
18%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Income from Continuing Operations
CHf10.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
Income from Continuing Operations
-CHf827.9m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-122%
|
CAGR 10-Years
N/A
|
See Also
What is Addex Therapeutics Ltd's Income from Continuing Operations?
Income from Continuing Operations
-10.6m
CHF
-10.6m
CHF
Based on the financial report for Dec 31, 2023, Addex Therapeutics Ltd's Income from Continuing Operations amounts to -10.6m CHF.
What is Addex Therapeutics Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-45%
-45%
Over the last year, the Income from Continuing Operations growth was 49%. The average annual Income from Continuing Operations growth rates for Addex Therapeutics Ltd have been 6% over the past three years , -45% over the past five years .
You don't have any saved screeners yet
